← Patent-cliff monitor small molecule EXPAREL BUPIVACAINE
Loss of exclusivity July 2044 latest FDA-listed patent expiry
Drug detail Brand name EXPAREL Active ingredient BUPIVACAINE Strength 266MG/20ML (13.3MG/ML) Dosage form INJECTABLE, LIPOSOMAL Route INJECTION Modality Small molecule FDA approval October 2011 Marketing status RX
Listed patents Patent Expires Type 12156940 July 2044 product 12370142 July 2044 product 12251468 July 2044 product 12318483 July 2044 use U-4152 11918565 February 2043 use U-3841 12226610 February 2043 use U-4150 11931459 March 2042 use U-3839 12296047 January 2041 product 11452691 January 2041 product 12151024 January 2041 product 11357727 January 2041 product 12144890 January 2041 product 11278494 January 2041 product 11304904 January 2041 product 11819574 January 2041 product 11925706 January 2041 product 11819575 January 2041 product 11033495 January 2041 product 11311486 January 2041 product 11179336 January 2041 product 11426348 January 2041 product
Regulatory exclusivity Code Expires I-929 November 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.